Jan. 19, 2007 -- The American Cancer Society issued its recommendations for using the new vaccine against cervical cancer -- recommendations that veer from those of other groups when it comes to vaccinating women over 18.
The guidelines, published in the American Cancer Society's journal, CA: A Cancer Journal for Clinicians, call for routinely vaccinating all girls aged 11 to 12.
They add that the vaccine, called Gardasil, may be given to girls as young as 9.
Girls 13 to 18 should be given a "catch-up" vaccine if they never received their vaccine, or did not complete the three-shot series.
However, unlike the CDC and the American College of Obstetricians and Gynecologists, the American Cancer Society (ACS) does not recommend routine vaccination for women 19 to 26.
"We don't believe the research is there among women 19 to 26 to justify universal vaccine recommendation," says ACS guidelines co-author Mark Einstein, MD, director of clinical research at Montefiore Medical Center and Einstein College of Medicine in New York City.
More than 11,000 new cases of cervical cancer will be diagnosed in 2007, with more than 3,600 deaths, according to ACS estimates.
The new cervical cancervaccines, combined with new information about the viral causes of cervical cancer, "present an unprecedented opportunity for global cervical cancer prevention," say the ACS guidelines.
Gardasil protects against cervical cancer by preventing infection by the human papillomavirus (HPV), the leading cause of cervical cancer.
HPV is a sexually transmitted virus, with dozens of strains.
But, according to ACS, two of those strains -- HPV 16 and 18 -- are responsible for up to 70% of all cervical cancers.